Bai Jiaofeng, Wang Xuan, Zheng Ruirui, He Miao, Zhang Yuexia, Zhang Zhichen, Yang Xiaolan, Pan Yaozhu
Department of Hematology, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, China.
Department of Endocrinology, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, China.
J Int Med Res. 2024 Aug;52(8):3000605241266590. doi: 10.1177/03000605241266590.
Myeloid sarcoma (MS) occurs in patients with acute myeloid leukemia (AML). In rare cases, MS can represent a form of blast transformation in patients with myeloproliferative neoplasms (MPN), myelodysplastic neoplasms (MDS), or MDS/MPN. The most frequent chromosomal alterations in MS are t(8;21) or inv(16), with other alterations being reported. Cases of MS in Janus kinase 2 (JAK2)-positive MDS with fibrosis are exceedingly rare. Here, we describe such a case. To the best of our knowledge, this is the first report of a JAK2 V617F mutation-positive MDS case occurring concurrently with MS involving the posterior aspect of the left seventh rib. No clear association has been previously demonstrated between the intramedullary AML cytogenetics and extramedullary disease occurrence. Interestingly, samples from the intramedullary MDS and extramedullary mass in this patient presented the same JAK2 V617F mutation. Following a treatment regimen of azacitidine and venetoclax, the patient achieved complete remission. The chest CT scan showed that the seventh posterior rib mass disappeared. This case provides valuable information for the potential future treatment of this disease.
髓系肉瘤(MS)发生于急性髓系白血病(AML)患者。在罕见情况下,MS可表现为骨髓增殖性肿瘤(MPN)、骨髓增生异常综合征(MDS)或MDS/MPN患者的原始细胞转化形式。MS最常见的染色体改变是t(8;21)或inv(16),也有其他改变的报道。Janus激酶2(JAK2)阳性且伴有纤维化的MDS患者发生MS的病例极为罕见。在此,我们描述这样一例病例。据我们所知,这是首例JAK2 V617F突变阳性的MDS病例同时并发累及左第七后肋后部的MS。此前尚未明确证实髓内AML细胞遗传学与髓外疾病发生之间存在关联。有趣的是,该患者髓内MDS和髓外肿块的样本呈现相同的JAK2 V617F突变。经过阿扎胞苷和维奈克拉的治疗方案后,患者实现了完全缓解。胸部CT扫描显示第七后肋肿块消失。该病例为这种疾病未来的潜在治疗提供了有价值的信息。